We would like to draw your attention to a few points regarding our programs:

Clinical Chemistry Program (CQH): Following requests from our participants, we have reduced the number of surveys from 35 to 22 per year. This format will remain in place for 2026. This program includes neonatal bilirubin.

Serum Protein Electrophoresis and Monoclonal Immunoglobulin Typing Program (EPS): This program includes the evaluation of monoclonal immunoglobulin typing.

Haemoglobin Electrophoresis Program (ELHB): Samples are provided with clinical contexts, allowing you to make an overall conclusion.

Improvements and Modifications to the Programs

Clinical Chemistry Program (CQH): We are offering an evaluation of free bilirubin results.

Serum Protein Electrophoresis and Monoclonal Immunoglobulin Typing Program (EPS): The quantification of the monoclonal peak can be reported as a percentage (%) and in g/L.

Blood Gas with Electrolytes Program (GDS): In 2026, this program includes the evaluation of creatinine results.

CO-Oximetry Program (COOX): Lyophilized samples have been removed. In 2026, we offer profiles with significant methemoglobin and carboxyhemoglobin levels.

Cerebrospinal Fluid Biochemistry Program (LCR): Only three laboratories submitted electrophoresis results on CSF in 2025; therefore, this test will not be repeated in 2026.

Urine Biochemistry Program (CMU): To follow evolving recommended practices, in 2026 we are adding the evaluation of the Albumin/Creatinine and Protein/Creatinine ratios.

Glomerular Filtration Rate (GFR) and Chronic Kidney Disease Assessment Program (CLAI): In 2026, this program will include the evaluation of urinary albumin, the Albumin/Creatinine ratio, and the KFRE (Kidney Failure Risk Equation). The Cockcroft calculation has been removed.

Therapeutic Drug Monotoring (CMED): In 2026, we are adding the monitoring of two drugs: lamotrigine and levetiracetam.

Complete Blood Count (stabilized blood) (NUM): We are adding the monitoring of the NRBC channel. However, we cannot guarantee the full range of concentrations covered for the NRBC channel in 2026.

CBC and Reticulocytes on fresh Blood (NFR): We are adding monitoring of erythroblasts and myelemia. For erythroblasts and myelemia, this is a pilot year, and we are currently unable to guarantee the range of values for 2026.

Biological Markers of Preeclampsia (PREE): We are offering entry of results for first-trimester preeclampsia risk assessment using supplier-specific risk calculation software (Thermo-Fisher, Perkin-Elmer, and Roche), based on the provided demographic data and the measured PlGF result.